Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

59459 1490631916HCLSReviewIrelandMarch2017.pdf
Energy Boardroom

The price is right for patient-switching on Biogen's new hemophilia med Alprolix

21.04.2014 / Fierce Pharma

With a pair of long-acting hemophilia meds on the way, Biogen Idec appears poised to shake up the market for the bleeding disease. And though recently approved Alprolix has yet to launch, it has already made waves: Biogen has priced it on par with older therapies, leaving competitors vulnerable to patient-switching.

Cover_HCLS_Ireland LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: